GenScript Biotech Corporation completes US$402 million follow-on offering by Legend Biotech Corporation
Clients GenScript Biotech Corporation
Jones Day represented GenScript Biotech Corporation in connection with a US$402 million follow-on offering by its Nasdaq-subsidiary Legend Biotech Corporation (NASDAQ: LEGN). GenScript Biotech Corporation is a well-recognized life sciences research and application service and product provider that applies its proprietary technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions. Its subsidiary Legend Biotech Corporation is a global, clinical-stage biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, it is developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell, T-cell receptor (TCR-T), and natural killer (NK) cell-based immunotherapy.